NanoViricides' Broad-Spectrum Antiviral NV-387 Offers Protection Against Influenza A and Bird Flu
NanoViricides' Broad-Spectrum Antiviral NV-387 Offers Protection Against Influenza A and Bird Flu
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly including Bird Flu H5N1 virus as well.
廣譜抗病毒納米藥物領域的全球領導者Nanoviricides, Inc.（紐約證券交易所代碼：NNVC）（“公司”）表示，NV-387 的超寬抗病毒活性譜包括甲型流感病毒，可能還包括禽流感H5N1病毒。
NanoViricides reports that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-influenza drugs.
nanoviricides報告說，在甲型/H3N2流感病毒肺部感染的致命動物模型中，與三種批准的抗流感藥物相比，NV-387 具有明顯優越的抗病毒作用。
We have recently performed a lethal lung infection study of mice infected with Influenza A/H3N2 that were treated with NV-387 or one of the three approved drugs for direct comparison: Oseltamivir (Tamiflu, Roche), Peramivir (Rapivab, Biocryst), and Baloxivir (Xofluza, Shionogi, Roche). In this study, NV-387 Oral treatment led to a survival lifespan of 15 days, compared to 10 days with Oseltamivir Oral treatment, 11 days with Peramivir I.V. treatment, and 11 days with Baloxivir Oral treatment, while the vehicle-treated and untreated (infected) animals survived only 8 days.
我們最近對感染了甲型H3N2流感的小鼠進行了一項致命的肺部感染研究，這些小鼠接受了 NV-387 或三種批准的直接比較藥物之一的治療：奧司他韋（達菲、羅氏）、培拉米韋（Rapivab、Biocryst）和巴洛西韋（Xofluza、Shionogi、羅氏）。在這項研究中，NV-387 口服治療的存活壽命爲15天，而奧司他韋口服治療爲10天，帕拉米韋靜脈注射治療爲11天，巴洛西韋口服治療爲11天，而經載體治療和未經治療（感染）的動物僅存活了8天。
Thus the anti-Influenza activity of NV-387 given orally was substantially superior to all three of the approved anti-influenza drugs, namely Tamiflu, Rapivab, and Xofluza.
因此，口服 NV-387 的抗流感活性大大優於所有三種批准的抗流感藥物，即達菲、Rapivab和Xofluza。
| Survival Lifespan of Lethally Infected Mice - Lung Infection with Influenza A H3N2 | |||
|---|---|---|---|
| Treatment | Survival, Days | Increase in Survival, Days | Increase in Survival, % |
| NV-387, Oral | 15 | 7 | 88% |
| Oseltamivir, Oral | 10 | 2 | 25% |
| Peramivir, I.V. | 11 | 3 | 38% |
| Baloxivir, Oral | 11 | 3 | 38% |
| Vehicle | 8 | 0 | 0% |
| 致命感染小鼠的存活壽命——甲型H3N2流感肺部感染 | |||
|---|---|---|---|
| 治療 | 生存，天數 | 存活率增加，天數 | 存活率提高，% |
| NV-387，口服 | 15 | 7 | 88% |
| 奧司他韋，口服 | 10 | 2 | 25% |
| 帕拉米韋，I.V. | 11 | 3 | 38% |
| 巴洛西韋，口服 | 11 | 3 | 38% |
| 車輛 | 8 | 0 | 0% |
Given the broad-spectrum of antiviral activity of NV-387 against viruses in many different virus families, we believe that its effectiveness against Influenza A/H3N2 is indicative of potential antiviral activity against most if not all Influenza A viruses.
鑑於 NV-387 對許多不同病毒家族中的病毒具有廣泛的抗病毒活性，我們認爲其對流感 A/H3N2 的有效性表明了對大多數（如果不是全部）甲型流感病毒的潛在抗病毒活性。
In particular, we believe, based on structural information, that the H5 hemagglutinin of H5N1 bird flu virus may be even more susceptible to NV-387 attack than the H3 hemagglutinin of the H3N2 virus. This is because H5 contains a long polybasic site sequence, which has biochemical affinity from electrostatic interactions with the antiviral ligand used in NV-387. This antiviral ligand is a sulfated proteoglycan mimetic.
特別是，根據結構信息，我們認爲，H5N1 禽流感病毒的 H5 血凝素可能比 H3N2 病毒的 H3 血凝素更容易受到 NV-387 的攻擊。這是因爲 H5 含有較長的多鹼基位點序列，該序列通過與 NV-387 中使用的抗病毒配體的靜電相互作用而具有生化親和力。這種抗病毒配體是硫酸化蛋白聚糖模擬物。
Thus it is very likely that NV-387 may have strong antiviral activity against the bird flu H5N1 virus, although further work is needed in this regard.
因此，NV-387 很可能對禽流感 H5N1 病毒具有很強的抗病毒活性，儘管在這方面還需要進一步努力。